Abstract
T here has been a renewed interest in the use of aerosolized antibiotics in cystic fibrosis (CF) patients during the past decade. Potential benefits of delivering antibiotics by aerosol include the following: direct delivery of antibiotics to the endobronchial site of infection; decreased toxicity as systemic absorption is limited; reduced cost; and less disruption to patients’ lives, especially when compared with IV antibiotic administration. Several reviews have summarized the published literature on the subject. 1‐3
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
